In the case of prostate cancer, a HER2 peptide-based vaccine demonstrated a trend in OS benefit for patients who developed positive IFN-γ-producing T cells during vaccination period (Peoples et al., 2005). This evidence concerns the gene ERBB2 and prostate carcinoma.